This page shows the latest ADC news and features for those working in and with pharma, biotech and healthcare.
The ADC has been recommended with doxorubicin, vinblastine and dacarbazine. Takeda has announced that the European Medicines Agency’s human medicines committee has recommended Adcetris (brentuximab vedotin) as part of a ... The Committee for Medicinal
apparent diffusion coefficient (ADC), was reduced by up to 38% following administration of PEGPH20.
Seagen and Genmab have announced positive results from a late-stage study of their antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin) in advanced cervical cancer.
BioNTech and Duality Biologics have expanded their existing agreement to include a third antibody-drug conjugate (ADC) for solid tumours. ... The companies announced the first deal covering two ADCs in April this year.
ADC said its decision to pause enrolment “enables time to evaluate data around the treatment-emergent adverse events and determine next steps”. ... Our top priority is the safety of every patient who participates in our clinical trials,” said ADC's
In combining the strengths of BeiGene and Duality, we believe more breakthrough ADC medicines will be brought to patients worldwide.”. ... In April, the company granted BioNTech the rights to co-develop and commercialise two of its ADC candidates for
More from news
Approximately 6 fully matching, plus 105 partially matching documents found.
The global biologics industry is thus witnessing steady growth, as new modalities – including antibody-drug conjugates (ADCs), bispecific proteins, and cell and gene therapies – now account for a significant one-third
This really does represent the next generation of antibody-drug conjugates (ADCs) via its significant bystander effect, and with potentially new targets and payloads (for example HER3 in lung cancer) to
One such example is through the development of antibody-drug conjugates (ADC) – monoclonal antibodies attached to biologically active cytotoxic drugs. ... The FDA recently granted accelerated approval for the ADC trastuzumab-deruxtecan in patients with
10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2. ... Kadcyla, the only other anti-HER2 ADC in this market, is a direct competitor and differentiation versus this established drug will be key.
The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Roche already has a
More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.
Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s
His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product
Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said:
These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.
conjugates (ADCs) for cancer.
More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.
Pegasus –the fifth largest healthcare agency in the UK –has merged with fellow Ashfield Health agencies Ashfield Digital and Creative (ADC) and Cambridge Biomarketing to form Mind Matter, a ‘global creative
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....